
Kallyope Presents Phase 2b Results of Elismetrep for Migraine at AAN Annual Meeting
Kallyope Reports Promising Phase 2b Results for Elismetrep, Introducing a Novel Mechanism for Acute Migraine Treatment Kallyope, a late-stage biotechnology company dedicated to developing innovative therapies for neurological and metabolic disorders, has announced encouraging results from its Phase 2b clinical…











